2003 Food and Drug Administration Pharmaceutical research 
PM360
NOVEMBER 12, 2024
They are difficult to diagnose early in a disease, the regulatory endpoints are often unprecedented and challenging, and many drugs struggle to get into the brain. The downside is that it also keeps most potential drug treatments from reaching the brain. Before Sage, he served as president of Alnylam Pharmaceuticals, Inc.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau.
Expert insights. Personalized for you.
52 
Let's personalize your content